Company Profile

Therabon Therapeutics (AKA: APC Biotechnology Services Inc~Clarassance Inc)
Profile last edited on: 2/27/2015      CAGE: 4A3F7      UEI: T1FKTLGMMDM6

Business Identifier: Secretoglobin-based biopharmaceutical products: novel protein therapeutics for treatment of respiratory diseases
Year Founded
2005
First Award
2007
Latest Award
2010
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

9430 Key West Avenue Suite 150
Rockville, MD 20850
   (240) 205-7271
   aprile.pilon@therabron.com
   www.therabron.com
Location: Single
Congr. District: 08
County: Montgomery

Public Profile

Formerly known as APC Biotechnology Services, Inc., and then Clarassance, Inc. in December 2014, the firm became Therabron Therapeutics. The firm is a privately held, clinical-stage, biopharmaceutical corporation developing a new class of drugs from the secretoglobin family of proteins. The firm's lead product is a proprietary preparation of recombinant human CC10 protein (rhCC10), having immediate clinical applications in respiratory diseases. The company is developing rhCC10 in persistent sinusitis, severe influenza-like illness (ILI), COPD, and neonatal bronchopulmonary dysplasia. A second secretoglobin protein product, based on the SCGB3A2 protein (CG1011), has completed proof of concept studies in pulmonary fibrosis. Several respiratory and autoimmune diseases may be caused, at least in part, by a lack of sufficient native CC10 protein in patients. Therabon is tackling development of a pharmaceutical therapy to replace CC10 with the synthetic version (rhCC10) in respiratory diseases characterized by inflammation and pre-existing CC10 deficiency. Restoration of CC10 function using rhCC10 has the potential to modify, or even rehabilitate, inflamed airways in diseases like asthma, chronic or recurrent sinusitis, COPD, and pulmonary fibrosis, rather than just treat the symptoms. RhCC10 has completed two Phase 1 clinical trials in which it demonstrated potent anti-inflammatory activity and significant long-term benefit in premature infants, who are known to lack sufficient native CC10 in their lungs.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
10-14

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2010 2 NIH $919,501
Project Title: Development of Novel Bioprocess Platform for Rapid, Economical Production of Peptides and Proteins
2007 1 NSF $150,000
Project Title: Novel Production Platform for Synthesis of Toxic Enzymes

Key People / Management

  Aprile L Pilon -- President

  Lisa Beth Ferstenberg -- Chief Medical Officer

  Philippe Rousseau -- Chief Financial Officer: